Salix, Progenics expect FDA verdict in April 2012 on Relistor in non-cancer OIC
This article was originally published in Scrip
Executive Summary
While Salix Pharmaceuticals investors saw reason to celebrate the US FDA's acceptance of the firm's supplemental new drug application (sNDA) for Relistor (methylnaltrexone bromide) as a subcutaneous injection to treat opioid-induced constipation (OIC) in patients with non-cancer pain, its partner Progenics Pharmaceuticals' stock dropped as low as 10.4%, or 68 cents, on 30 August.